Showing results (41-50 of 68) with videos related to

Sort By:
Pageof 7
Pathogens & Immunity|September 9, 2024
Impact of SARS-CoV-2 Resistance to Antiviral Monoclonal Antibody Therapy on Neutralizing Antibody ResponseMarc-Kendy Paul, Manish C Choudhary, Amy L Heaps, et al.
Open Forum Infectious Diseases|December 5, 2022
Predictors of SARS-CoV-2 RNA From Nasopharyngeal Swabs and Concordance With Other Compartments in Nonhospitalized Adults With Mild to Moderate COVID-19Carlee Moser, Jonathan Z Li, Joseph J Eron, et al.
Biorxiv : the Preprint Server for Biology|December 4, 2023
SARS-CoV-2 monoclonal antibody treatment followed by vaccination shifts human memory B cell epitope recognition suggesting antibody feedbackCamila H Coelho, Nathaniel Bloom, Sydney I Ramirez, et al.
Eclinicalmedicine|October 19, 2023
Safety and efficacy of inhaled interferon-β1a (SNG001) in adults with mild-to-moderate COVID-19: a randomized, controlled, phase II trialPrasanna Jagannathan, Kara W Chew, Mark J Giganti, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 11, 2021
Randomized Trial of Ruxolitinib in Antiretroviral-Treated Adults With Human Immunodeficiency VirusVincent C Marconi, Carlee Moser, Christina Gavegnano, et al.
JCI Insight|November 15, 2022
Bamlanivimab therapy for acute COVID-19 does not blunt SARS-CoV-2-specific memory T cell responsesSydney I Ramirez, Alba Grifoni, Daniela Weiskopf, et al.
The Journal of Infectious Diseases|January 20, 2023
Phase 2 Safety and Antiviral Activity of SAB-185, a Novel Polyclonal Antibody Therapy for Nonhospitalized Adults With COVID-19Babafemi O Taiwo, Kara W Chew, Carlee Moser, et al.
The Journal of Infectious Diseases|August 31, 2023
Variant-Specific Viral Kinetics in Acute COVID-19Ruy M Ribeiro, Manish C Choudhary, Rinki Deo, et al.
JCI Insight|December 20, 2024
Early antiviral CD4+ and CD8+ T cells are associated with upper airway clearance of SARS-CoV-2Sydney I Ramirez, Paul G Lopez, Farhoud Faraji, et al.
Iscience|March 24, 2025
Tixagevimab/cilgavimab or placebo for COVID-19 in ACTIV-2: Safety, pharmacokinetics and neutralizing and anti-drug antibodiesRachel A Bender Ignacio, Kara W Chew, Carlee Moser, et al.
Pageof 7